Standard Chemical & Pharmaceutical Co., Ltd. (TPE:1720)
Taiwan · Delayed Price · Currency is TWD 60.40
-0.70 (-1.15%)
Feb 2, 2026, 1:35 PM CST
TPE:1720 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 6,911 | 6,789 | 6,240 | 5,851 | 4,604 | 4,305 | |
Revenue Growth (YoY) | 3.02% | 8.81% | 6.64% | 27.09% | 6.94% | 9.35% |
Cost of Revenue | 3,998 | 3,801 | 3,514 | 3,364 | 2,536 | 2,386 |
Gross Profit | 2,912 | 2,989 | 2,725 | 2,488 | 2,068 | 1,920 |
Selling, General & Admin | 1,300 | 1,293 | 1,209 | 1,100 | 948.47 | 992.48 |
Research & Development | 273.84 | 288.09 | 266.27 | 251.88 | 241.79 | 227.21 |
Operating Expenses | 1,567 | 1,592 | 1,466 | 1,369 | 1,191 | 1,213 |
Operating Income | 1,345 | 1,397 | 1,260 | 1,118 | 876.83 | 706.63 |
Interest Expense | -8.03 | -15.07 | -25.42 | -18.78 | -7.25 | -7.57 |
Interest & Investment Income | 120.51 | 50.48 | 76.84 | 39.45 | 24.99 | 26.52 |
Earnings From Equity Investments | -7.91 | -11.36 | 41.56 | 61.37 | -6.16 | 3.05 |
Currency Exchange Gain (Loss) | -24.78 | 86.85 | 5.62 | 170.44 | -25.6 | -33.07 |
Other Non Operating Income (Expenses) | 45.43 | 51.08 | 30.1 | 35.44 | 77.66 | 77.29 |
EBT Excluding Unusual Items | 1,471 | 1,558 | 1,388 | 1,406 | 940.47 | 772.85 |
Gain (Loss) on Sale of Investments | 9.53 | -0.67 | 5.53 | 1.36 | 1.46 | 0.2 |
Gain (Loss) on Sale of Assets | -1.27 | -5.47 | 1.27 | -7.78 | 73.78 | -0.08 |
Asset Writedown | - | - | - | - | -1.81 | - |
Other Unusual Items | 0.12 | -0.19 | 0.02 | 0.11 | -66.45 | -0.04 |
Pretax Income | 1,479 | 1,627 | 1,438 | 1,400 | 1,014 | 772.93 |
Income Tax Expense | 248.11 | 333.05 | 279.94 | 246.31 | 176.95 | 147.37 |
Earnings From Continuing Operations | 1,231 | 1,294 | 1,158 | 1,154 | 836.8 | 625.56 |
Minority Interest in Earnings | -337.85 | -413.81 | -323.04 | -338.21 | -130.07 | -101.39 |
Net Income | 893.09 | 880.5 | 834.89 | 815.41 | 706.73 | 524.17 |
Net Income to Common | 893.09 | 880.5 | 834.89 | 815.41 | 706.73 | 524.17 |
Net Income Growth | 5.37% | 5.46% | 2.39% | 15.38% | 34.83% | 39.23% |
Shares Outstanding (Basic) | 179 | 179 | 179 | 179 | 179 | 179 |
Shares Outstanding (Diluted) | 179 | 179 | 179 | 179 | 179 | 179 |
Shares Change (YoY) | 0.01% | 0.01% | 0.00% | -0.02% | 0.02% | 0.01% |
EPS (Basic) | 5.00 | 4.93 | 4.67 | 4.56 | 3.95 | 2.93 |
EPS (Diluted) | 5.00 | 4.92 | 4.67 | 4.56 | 3.95 | 2.93 |
EPS Growth | 5.44% | 5.35% | 2.41% | 15.44% | 34.81% | 39.52% |
Free Cash Flow | 1,175 | 1,098 | 710.83 | 31.78 | 613.56 | 570.06 |
Free Cash Flow Per Share | 6.57 | 6.14 | 3.97 | 0.18 | 3.43 | 3.19 |
Dividend Per Share | 2.800 | 2.800 | 2.700 | 2.500 | 2.500 | 1.800 |
Dividend Growth | 3.70% | 3.70% | 8.00% | - | 38.89% | 20.00% |
Gross Margin | 42.14% | 44.02% | 43.68% | 42.51% | 44.91% | 44.59% |
Operating Margin | 19.47% | 20.57% | 20.19% | 19.11% | 19.05% | 16.41% |
Profit Margin | 12.92% | 12.97% | 13.38% | 13.94% | 15.35% | 12.17% |
Free Cash Flow Margin | 17.00% | 16.18% | 11.39% | 0.54% | 13.33% | 13.24% |
EBITDA | 1,742 | 1,772 | 1,579 | 1,389 | 1,073 | 917.22 |
EBITDA Margin | 25.21% | 26.09% | 25.30% | 23.74% | 23.31% | 21.30% |
D&A For EBITDA | 396.94 | 375.06 | 319.44 | 270.67 | 196.31 | 210.59 |
EBIT | 1,345 | 1,397 | 1,260 | 1,118 | 876.83 | 706.63 |
EBIT Margin | 19.47% | 20.57% | 20.19% | 19.11% | 19.05% | 16.41% |
Effective Tax Rate | 16.78% | 20.47% | 19.47% | 17.59% | 17.46% | 19.07% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.